FDA warned Expert Aesthetics over website claims that its compounded semaglutide and tirzepatide are generic Ozempic and Mounjaro.
What happened
FDA reviewed the website https://erasingage.com in August 2025 and found it offered compounded semaglutide and tirzepatide. FDA said the site called them generic versions of Ozempic and Mounjaro, which falsely implies they are the same as FDA-approved products. FDA therefore called the products misbranded—meaning their labeling is false or misleading—and said selling them across state lines is prohibited.
What FDA found
The website called compounded semaglutide a generic version of Ozempic, falsely implying it is the same as an FDA-approved drug when compounded drugs are not FDA-approved.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The website called compounded tirzepatide a generic version of Mounjaro, falsely implying it is the same as an FDA-approved drug when compounded drugs are not FDA-approved.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]FDA says the falsely labeled compounded drugs were shipped or offered for shipping across state lines, which is a prohibited act.
FDCA section 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA tells Expert Aesthetics to take immediate action, including ceasing the misleading claims, and to respond within 15 working days with the steps taken, plans to prevent recurrence, and supporting documents.
Who should pay attention
- telehealth companies selling compounded semaglutide or tirzepatide
- compounding pharmacies and clinics that advertise GLP-1 products
- website marketing and regulatory teams for drug sellers
This is a summary. Read the original letter on fda.gov.